You are here: Industry Insights > SARS-CoV-2

News List

Hoth Announces Positive Preclinical Results for Novel COVID-19 Therapeutic americanpharmaceuticalreview
March 29, 2021
Hoth Therapeutics announced new in vitro data demonstrating SARS-CoV-2 antiviral activity for its lead peptide candidate for HT-002, a novel therapeutic targeted for the treatment of COVID-19.
Eli Lilly Stops Distribution of Bamlanivimab as COVID-19 Treatment americanpharmaceuticalreview
March 29, 2021
The US government in coordination with Eli Lilly said it will no longer distribute the COVID-19 monoclonal antibody therapy bamlanivimab for use on its own.
NIH-funded study finds evidence that SARS-CoV-2 infects cells in mouth pharmaceutical-technology
March 29, 2021
A team led by scientists at the National Institutes of Health (NIH) and the University of North Carolina (UNC) at Chapel Hill in the US has found evidence that SARS-CoV-2, which causes Covid-19, infects cells in the mouth.
Will COVID-19 vaccines need to be adapted regularly? worldpharmanews
March 26, 2021
Influenza vaccines need to be evaluated every year to ensure they remain effective against new influenza viruses. Will the same apply to COVID-19 vaccines?
IONTAS Identifies Novel SARS-CoV-2 Neutralizing Antibodies americanpharmaceuticalreview
March 26, 2021
IONTAS and FairJourney Biologics have announced the identification of neutralizing antibodies, which bind to multiple emerging SARS-CoV-2 variants.
FDA Authorizes First Machine Learning-Based Screening Device that May Indicate COVID-19 Infection americanpharmaceuticalreview
March 26, 2021
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the first machine learning-based Coronavirus Disease 2019 (COVID-19) non-diagnostic screening device that identifies certain biomarkers that are ...
Individual SARS-CoV-2 neutralising antibody immunity lasts from days to decades worldpharmanews
March 25, 2021
Scientists from Duke-NUS Medical School, the National Centre for Infectious Diseases (NCID) and the Agency for Science, Technology and Research (A*STAR) Infectious Diseases Labs found that antibodies against SARS-CoV-2 wane at different rates, lasting ...
FDA Authorizes Revisions to Fact Sheets for SARS-CoV-2 Variants under EUA americanpharmaceuticalreview
March 25, 2021
The U.S. Food and Drug Administration (FDA) authorized revised fact sheets for health care providers to include additional information on susceptibility of SARS-CoV-2 variants to each of the monoclonal antibody (mAb) therapies that are available ...
FDA Permits Marketing of First SARS-CoV-2 Diagnostic Test Using Traditional Premarket Review Process americanpharmaceuticalreview
March 24, 2021
The U.S. Food and Drug Administration (FDA) granted marketing authorization of the BioFire Respiratory Panel 2.1 (RP2.1), a diagnostic test for the simultaneous qualitative detection and identification of multiple respiratory viral and ...
Cytocom Receives IND for CYTO-205 Trial for COVID-19 americanpharmaceuticalreview
March 23, 2021
Cytocom announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 2 clinical trial to evaluate the safety and efficacy of CYTO-205 as a treatment to slow or halt the progression of ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 61 62 Next page